Amyloid-β concentration and structure influences the transport and immunomodulatory effects of IVIG

Journal of Neurochemistry

Volumn 130, Issue 1, 2014, Pages 136-144

  Wuest, Diane M ^a   Lee, Kelvin H ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

Alzheimer's disease; amyloid ; blood brain barrier; in vitro blood brain barrier model; inflammation; intravenous immunoglobulin

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN; MONOCYTE CHEMOTACTIC PROTEIN 1; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); IMMUNOLOGIC FACTOR; PEPTIDE FRAGMENT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG TRANSPORT; ELECTRIC RESISTANCE; ENDOTHELIUM CELL; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEWBORN; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM;

AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS;

EID: 84903168717     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12678     Document Type: Article

References (47)

1. Bach J. P., and, Dodel R., (2012) Naturally occurring autoantibodies against β-Amyloid. Adv. Exp. Med. Biol. 750, 91-99.
2. Bamberger M. E., and, Landreth G. E., (2002) Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist 8, 276-283. (Pubitemid 34538795)
3. Banks W., and, Erickson M., (2010) The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 37, 26-32.
4. Bell R. D., and, Zlokovic B. V., (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118, 103-113.
5. Cattepoel S., Schaub A., Ender M., et al,. (2013) Intravenous immunoglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro. PLoS ONE 8, e63162.
6. Cecchelli R., Berezowski V., Lundquist S., Culot M., Renftel M., Dehouck M. P., and, Fenart L., (2007) Modelling of the blood-brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 6, 650-661. (Pubitemid 47202487)
7. Choi C., Jeong J. H., Jang J. S., Choi K., Lee J., Kwon J., Choi K. G., Lee J. S., and, Kang S. W., (2008) Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. J. Clin. Neurol. 4, 84-88.
8. Citron M., (2010) Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 9, 387-398.
9. Dahlgren K. N., Manelli A. M., Stine W. B., Jr, Baker L. K., Krafft G. A., and, LaDu M. J., (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046-32053. (Pubitemid 34969015)
10. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., and, Oertel W., (2010) Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 70, 513-528.
11. Dodel R., Rominger A., Bartenstein P., et al,. (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomized, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 12, 233-243.
12. Dong Y., and, Benveniste E. N., (2001) Immune function of astrocytes. Glia 36, 180-190. (Pubitemid 33055906)
13. Fändrich M., Schmidt M., and, Grigorieff N., (2011) Recent progress in understanding Alzheimer's β-amyloid structures. Trends Biochem. Sci. 36, 338-345.
14. Farina C., Aloisi F., and, Meinl E., (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol. 28, 138-145. (Pubitemid 46283692)
15. Farkas E., and, Luiten P. G., (2001) Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64, 575-611. (Pubitemid 32304447)
16. Felgenhauer K., (1974) Protein size and cerebrospinal fluid composition. Klin. Wochenschr. 52, 1158-1164.
17. Fenoglio C., Galimberti D., Lovati C., et al,. (2004) MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol. Aging 25, 1169-1173. (Pubitemid 39094019)
18. Galimberti D., Schoonenboom N., Scarpini E., and, Scheltens P., (2003) Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients. Ann. Neurol. 53, 547-548. (Pubitemid 36373272)
19. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Bouwman F., Venturelli E., Guidi I., Blankenstein M. A., Bresolin N., and, Scarpini E., (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch. Neurol. 63, 538-543.
20. Gibb S. L., Boston-Howes W., Lavina Z. S., Gustincich S., Brown R. H., Jr, Pasinelli P., and, Trotti D., (2007) A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. J. Biol. Chem. 282, 32480-32490. (Pubitemid 350106448)
21. Gonzalez-Velasquez F. J., Kotarek J. A., and, Moss M. A., (2008) Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J. Neurochem. 107, 466-477.
22. Hawkins B. T., and, Davis T. P., (2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57, 173-185. (Pubitemid 41043883)
23. Hurwitz A. A., Lyman W. D., and, Berman J. W., (1995) Tumor necrosis factor alpha and transforming growth factor beta upregulate astrocyte expression of monocyte chemotactic protein-1. J. Neuroimmunol. 57, 193-198.
24. Jeynes B., and, Provias J., (2011) The case for blood-brain barrier dysfunction in the pathogenesis of Alzheimer's disease. J. Neurosci. Res. 89, 22-28.
25. [1-42]-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca?-calcineurin signaling. J. Neurosci. 32, 8845-8854.
26. Magga J., Puli L., Pihlaja R., et al,. (2010) Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J. Neuroinflammation 7, 90.
27. Marco S., and, Skaper S. D., (2006) Amyloid β-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci. Lett. 401, 219-224. (Pubitemid 44250979)
28. McGeer P. L., and, McGeer E. G., (1998) Mechanisms of cell death in Alzheimer disease-immunopathology. J. Neural Transm. Suppl. 54, 159-166. (Pubitemid 28539352)
29. Morgan D., (2006) Immunotherapy for Alzheimer's disease. J. Alzheimers Dis. 9 (3 Suppl), 425-432. (Pubitemid 44255489)
30. Neff F., Wei X., Nölker C., Bacher M., Du Y., and, Dodel R., (2008) Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun. Rev. 7, 501-507.
31. Nichols M. R., Moss M. A., Reed D. K., Lin W. L., Mukhopadhyay R., Hoh J. H., and, Rosenberry T. L., (2002) Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry 41, 6115-6127. (Pubitemid 34498918)
32. Nimmerjahn F., and, Ravetch J. V., (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu. Rev. Immunol. 26, 513-533. (Pubitemid 351600384)
33. Relkin N. R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R. W., Younkin S., Younkin L., Schiff R., and, Weksler M. E., (2009) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30, 1728-1736.
34. Rogers J., Webster S., Lue L.-F., Brachova L., Civin W. H., Emmerling M., Shivers B., Walker D., and, McGeer P., (1996) Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging 17, 681-686. (Pubitemid 26348868)
35. Schwab C., and, McGeer P. L., (2008) Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 13, 359-369. (Pubitemid 352039027)
36. Schwab I., and, Nimmerjahn F., (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176-189.
37. Sharma H. S., Castellani R. J., Smith M. A., and, Sharma A., (2012) The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Int. Rev. Neurobiol. 102, 47-90.
38. Sivanesan S., Tan A., and, Rajadas J., (2013) Pathogenesis of Abeta oligomers in synaptic failure. Curr. Alzheimer Res. 10, 316-323.
39. St-Amour I., Pare I., Alata W., Coulombe K., Ringuette-Goulet C., Drouin-Ouellet J., Vandal M., Soulet D., Bazin R., and, Calon F., (2013) Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier. J. Cereb. Blood Flow Metab. 33, 1983-1992.
40. Stine W. B., Jr, Dahlgren K. N., Krafft G. A., and, LaDu M. J., (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278, 11612-11622. (Pubitemid 36792723)
41. Sudduth T. L., Greenstein A., and, Wilcock D. M., (2013) Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J. Neurosci. 33, 9684-9692.
42. Sun Y. X., Minthon L., Wallmark A., Warkentin S., Blennow K., and, Janciauskiene S., (2003) Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 16, 136-144. (Pubitemid 36736999)
43. Thies W., and, Bleiler L., (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 9, 208-245.
44. White J. A., Manelli A. M., Holmberg K. H., Van Eldik L. J., and, Ladu M. J., (2005) Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol. Dis. 18, 459-465. (Pubitemid 40332705)
45. Wilhelm I., Fazakas C., and, Krizbai I. A., (2011) In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. 71, 113-128.
46. Wuest D. M., and, Lee K. H., (2012) Optimization of endothelial cell growth in a murine in vitro blood-brain barrier model. Biotechnol. J. 7, 409-417.
47. Wuest D. M., Wing A. M., and, Lee K. H., (2013) Membrane configuration optimization for a murine in vitro blood-brain barrier model. J. Neurosci. Methods 212, 211-221.